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Abstract
Background: The Hospital Acquired Condition Strategy (HACS) denies payment for venous thromboembolism (VTE) after
total knee arthroplasty (TKA). The intention is to reduce complications and associated costs, while improving the quality of
care by mandating VTE prophylaxis. We applied a system dynamics model to estimate the impact of HACS on VTE rates, and
potential unintended consequences such as increased rates of bleeding and infection and decreased access for patients
who might benefit from TKA.
Methods and Findings: The system dynamics model uses a series of patient stocks including the number needing TKA,
deemed ineligible, receiving TKA, and harmed due to surgical complication. The flow of patients between stocks is
determined by a series of causal elements such as rates of exclusion, surgery and complications. The number of patients
harmed due to VTE, bleeding or exclusion were modeled by year by comparing patient stocks that results in scenarios with
and without HACS. The percentage of TKA patients experiencing VTE decreased approximately 3-fold with HACS. This
decrease in VTE was offset by an increased rate of bleeding and infection. Moreover, results from the model suggest HACS
could exclude 1.5% or half a million patients who might benefit from knee replacement through 2020.
Conclusion: System dynamics modeling indicates HACS will have the intended consequence of reducing VTE rates.
However, an unintended consequence of the policy might be increased potential harm resulting from over administration
of prophylaxis, as well as exclusion of a large population of patients who might benefit from TKA.
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Introduction
Recent public debate on health care reform has renewed focus
on patient safety and cost containment [1]. A value-based health
care strategy strives to ‘bend the healthcare cost curve’ by
publically reporting rates of post-operative complications and
adherence to quality of care and patient safety measures [2].
Value-based systems assume institutions will minimize complica-
tion rates thereby costs will be reduced while improving the quality
of care. Value-based mandates, however, may have unintended
consequences on overall complications, unanticipated costs, or
reduced access for individuals who may benefit from a treatment.
As a part of the Deficit Reduction Act of 2005, the Secretary of
Health and Human Services (USA) identified high cost and high
volume procedures where preventable hospital acquired condi-
tions were reimbursed at higher rates [3]. For example, total knee
arthroplasty (TKA) patients who develop venous thromboembo-
lism (VTE), a term used to collectively describe deep vein
thrombosis (DVT) and pulmonary embolism (PE), accrue higher
costs than those who do not experience this condition. Evidence-
based guidelines suggest administering prophylaxis medications
(anti-clotting blood thinners) reduces VTE rates [4,5,6]. To
encourage adherence to these guidelines, beginning on October 1,
2008, the ‘‘hospital acquired condition’’ strategy (HACS) no
longer reimburses inpatient costs after a newly diagnosed VTE if
recommended prophylaxis was not administered prior to TKA
procedures [7].
Every year in the U.S., over 185,000 VTE cases are diagnosed
in patients aged 45 years or older [8]. More than 35% occur after
surgical events [9], frequently leading to long-term disability or
death [10,11]. Certain clinical conditions, such as malignant
neoplasm, trauma, congestive heart failure, obesity, multiparity,
advancing age and hypercoagulability increase VTE risk
[12,13,14]. Despite evidence suggesting its efficacy to reduce
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complication risk, 41 to 84% of the patients do not receive
recommended VTE prophylaxis [15,16]. Patients receiving TKA
have increased risk of VTE, and recommended prophylaxis
reduces this risk [17]. Therefore, a policy that encourages anti-
thrombotic prophylaxis seems reasonable.
System Dynamics [18] has been used to model the consequenc-
es of national smoking cessation initiatives [19], smallpox
vaccination [20], and prevention vs. management of chronic
disease, [21]. Changes in health care policy can affect access,
reimbursement and clinical outcomes. Complex interrelationships
have multiple clinical ramifications on patients, payors, providers,
and hospital administrators. System Dynamics uses stock and flow
diagrams, feedback loops and various ‘what if scenarios’ to portray
the casual relationships among these elements and predict long
term implications of these complex interactions [22]. For example,
improving adherence to prophylaxis guidelines may decrease VTE
rates, but this may also increase the rates of bleeding which in turn
may increase infection rates. Mandating VTE prophylaxis may
reduce access to TKA for patients who have increased risk of
bleeding.
This study applies system dynamics to estimate the impact of
HACS on rates of VTE and other surgical complications (such as
bleeding and infection). We hypothesize that the increased rates of
VTE prophylaxis will actually increase rates of bleeding and
infection [23]. Additionally, patient subgroups who might benefit
from a knee replacement but have increased risk of bleeding will
accumulate.
Methods
Modeling Context
The Hospital Acquired Condition Strategy (HACS) enacted by
federal legislation applied to Medicare reimbursement for VTE
[7]. The majority of patients eligible for Medicare are older than
age 65, and VTE risk varies considerably by age [24], so patients
younger than age 65 were excluded when developing parameters
for the model. Typical Medicare reimbursement to hospitals is
$10,000, $13,000 for patients with a major comorbidity or those
who experience a complication [25]. The rationale for imple-
menting the HACS were the low rates of guideline-recommended
proplylaxis [26]. Some argue is neither preventable nor accurately
measurable [27]. Nearly half of patients with a DVT detectable by
ultrasound do not experience clinical symptoms [28]. Patients with
DVT risk factors will more likely receive prophylaxis and can be
excluded from HACS policy by indicating ‘‘presence on admission
can not be determined’’ [29]. On the other hand, clinicians may
be hesitant to administer DVT prophylaxis to patients with
increased risk of bleeding so these patients might be affected by the
policy change.
Literature Review
Citations from the Federal Register ‘‘hospital acquired condi-
tion’’ policy [7] and the Surgeon General’s Call to Action to
prevent DVT and PE [30] were used to define an initial set of risk
factors and rates of DVT, PE, and bleeding in various populations
as well as potential risk factors. Additional studies were identified
through PubMed database by taking the intersection of each risk
factor and the terms venous thrombosis, DVT, PE, or DVT
prophylaxis.
Expert Interview
Certain model inputs such as willingness to treat patients with
increased risk of DVT or bleeding, rates of surgical site infection in
patients with excessive bleeding, and those harmed by DVT and
bleeding were not clearly described in the literature. Three
arthroplasty surgeons at the University of California, San
Francisco (UCSF) were queried to obtain a range for these values
through mutual agreement. (Refer Information S1 -Questions
asked to expert panel) All three surgeons are board certified knee
specialists performing a large volume of total knee replacement
procedures in a University hospital setting.
Model Parameters
The parameters included in the model are either stocks,
represented as boxes in Figure 1 or causal elements represented
at the ends of arrows. Stocks, accumulate over time with the
quantity regulated by influx and efflux rates. For example, the
stock of patients who can benefit with TKA increase as the
number of patients with osteoarthritis in the overall population
increases. Meanwhile, patients deemed ineligible and those who
receive TKA decrease this stock. The causal elements affect results
derived from the model but do not accumulate over time. An
example of a causal element is the percentage of patients receiving
TKA or fraction of patients with postoperative bleeding who later
developed a surgical site infection.
Model Relationships
The movement of patients through the system is regulated by
the relationships between the stocks and causal elements. A flow is
represented by a thick, double-lined arrow emerging out of or
entering into a stock. Causal links illustrating the effect of the
causal variables are represented by thin arrows. Blue arrows
represent causal effects that may increase or decrease flows, red
and green arrows indicate the impact of HACS.
Policy Intervention
We compare two simulation scenarios, with and without HACS.
The HACS scenario represents the potential result of withholding
reimbursement for hospital care associated with the treatment of
VTE when VTE prophylaxis is not administered prior to TKA.
VTE rates are those indicated when Enoxaparin, the prophylaxis
recommened by both the American College of Chest Physicians
(ACCP) [5] and the American Academy of Orthopaedic Surgeons
(AAOS) [6], is or is not administered. We assume VTE rates
reported in clinical trials would be achieved with increased
adherence to VTE prophylaxis guidelines.
Dynamics Hypothesis
The ideal scenario as envisioned by those who implemented
HACS policy is a hypothesis that rates of VTE will decrease over
time, while rates of surgical complications and disparity remain
stable.
The Systems Dynamics Model
Vensim software was used to design and simulate the System
Dynamics model [18]. The first parameter illustrated in Figure 1 is
the stock representing the prevalence (9.7 million) of patients over
age 65 suffering with symptomatic knee osteoarthritis (OA) [24].
As the model cycles from 2008 through 2020, the number of
patients in this stock is dependent on birth and death rates. The
number of patients requiring TKA are those with OA who do not
respond to non-operative therapy. These patients could either
undergo TKA or be excluded, depending on eligibility require-
ments. The stock entitled ‘‘Patients with Knee OA requiring TKA
who will NOT be operated’’ represents patients with clinical
conditions (such as malignant neoplasm, morbid obesity, immobile
standing position, hypercoagulable state, etc) who are not eligible
System Dynamics for Total Knee Arthroplasty
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for TKA. Patients undergoing TKA could have an uneventful
course, a VTE, or a bleeding complication. Patients who
experience excess bleeding may develop a surgical site infection
resulting from hematoma, evacuation or prolonged wound
drainage [31,32]. Of those experiencing VTE, a fraction will die
due to fatal PE, some have to undergo at least 6 months of oral
anticoagulation, and those who will not be diagnosed with VTE
may experience chronic venous insufficiency requiring long term
mechanical compression therapy. We modeled four complication
scenarios (bleeding, infection, diagnosed and undiagnosed VTE),
with fractions of harmed patients.
The model examined hypothetical simulations over a period of
12 years from 2008 continued through 2020. The stocks examined
were the number of patients experiencing VTE, bleeding,
infection, or were deemed ineligible for surgery individually, as
well as the cumulative number of harmed patients per year. Inputs
for the model are indicated in Table 1. The parameters assume a
1.5% decrease (from 14.4–12.9%) in TKA eligibility among
patients with OA with HACS. Higher rates of bleeding (9.6% vs.
1.4%) and lower rates of VTE (2 vs. 5%) due to increased
administrating VTE prophylaxis with HACS. We also speculate
that a fraction of VTE diagnoses (25 vs. 15%) will be missed
because of a disincentive with HACS to identify the condition, and
that 10% of patients with a missed diagnosis will be harmed. The
range of values for each parameter that were modeled in the
sensitivity analyses are also indicated in Table 1.
Results
Model stock outputs indicate HACS results in a 3-fold decrease
in VTE rates (Table 2). However, the fraction of HACS with
bleeding complications associated is 6-fold higher, and 6-fold more
patients are potentially ineligible for TKA per year with HACS in
place.
The cumulative potential harm over time due to VTE, bleeding,
infection and denied access that could be attributed to HACS is
illustrated in Figure 2. The model indicates the fraction harmed
with HACS will be 2.8 times higher in 2011, 3.3 times in 2014, 3.4
times in 2017 and 3.5 times in 2020. The increase in the total
number of adults harmed by the HACS reaches half a million
people by year 2020. Sensitivity analysis indicates this increase
might be as small as 43,000 and as high as 980,000.
The fraction of patients affected by policy stabilizes as the model
reaches equilibrium (Figure 3). HACS increased the percentage of
patients suffering from OA pain who could benefit from, but do
not receive TKA by 1.6% (2.2% with HACS, 0.6% without).
Figure 1. An illustration of the stocks, causal elements, relationships and impact of HACS in the system dynamics model.
doi:10.1371/journal.pone.0030578.g001
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Sensitivity analysis indicates the percentage of patient denied TKA
with HACS may be as high as 3.4% and as low as 0.95%, and
0.79–0.36% without.
Discussion
Several interventions [33], including physician alerts [34],
decision support informatics [35], and regular audits [36] are
shown to increase the rates of VTE prophylaxis. Despite these
efforts, only 60% of TKA patients receive enoxaparin as
recommended by ACCP guidelines [16]. The monetary incentive
mandated by HACS, not reimbursing costs resulting from VTE
when VTE prophylaxis was not administered, was effective for
decreasing VTE rates, but our model suggests HACS will result in
an overall 6-fold increase in complication rates. While others have
suggested the possibility of unintended consequences [37], this
study indicates half a million people might be harmed by HACS
by the year 2020. Furthermore, the fraction of Americans who
could benefit, but are denied for TKA is increased 1.6% with
HACS because of their risk of developing a VTE complication
which would place the providers and hospitals at financial risk for
the episode of care.
Mandating VTE prophylaxis increases the risk of prolonged
wound drainage, extended hospital stay, and surgical site infection
[31,32,38]. Surgical site infection measureably reduces health-
related quality of life [39]. We did not attempt to estimate whether
savings to Medicare by refusing to reimburse care for VTE
complications with HACS is offset by the cost of prophylaxis,
extended hospitalization and readmission resulting from bleeding
and infection complications. Other potential model parameters
were not studied as well. The efficacy of recommended
prophylaxis to reduce the risk of death due to a PE when
compared to aspirin in TKA patients remains controversial [6].
Other prophylaxis regimens may result in a different impact of
HACS. Bleeding rates for this study were based on published
clinical experience with low molecular weight heparin.
A policy that penalizes the occurrence of adverse outcomes will
likely decrease access to at-risk patients. The potential for inequity
may be greater than estimated in this model. Kahneman’s
Prospect Theory suggests aversion of loss is psychologically twice
as powerful as the potential for gain [40]. The desire to avoid
HACS consequences could result in overly aggressive VTE
prophylaxis, under reporting of VTE, and exclusion of patients
who could benefit from TKA. Our model estimates the policy will
exclude over 35,000 patients/year. Access to care is driven by
perceptions of both the surgeon and patient. Only a third of
surveyed patients with painful osteoarthritis were willing to
consider TKA as a treatment option [41]. TKA significantly
improves the quality of life of patients with osteoarthritis
[42,43,44]. Typical patients experience a gain of more than one
quality adjusted life year (QALY from 6.8 to 8.0 with TKA) [45].
Elderly patients with comorbidity and those living in poverty
might be comparable to those who are excluded by HACS. These
patients experienced a similar QALY gain, (0.8, 5.8 to 6.6 with
TKA) [45].
Table 1. Model parameters, minimum and maximum range, and reference sources.
Baseline (%)
Sensitivity Analysis
(minimum - maximum
value) Reference
Without HACS With HACS Without HACS With HACS
Eligibility rate 14.4% 12.9% 13.4–15.4% 11.9–13.9% [49,59], Expert panel
Bleeding rate 1.4% 9.6% 0.4–2.4% 7.6–10.6% [60]
VTE rate 5% 2% 3–7% 0.5–4% [21, 61, 62]
VTE diagnosis rate 85% 75% 75–90% 65–85% Expert panel
Infection rate 10% 10% 5–20% 5–20% [32,33,38] Expert panel,
Bleeding harm rate 58% 58% 46–70% 46–70% [62]
VTE harm rate 75% 75% 65–85% 65–85% [63], Expert panel
Missed diagnosis harm
rate
10% 10% 5–20% 5–20% [64], Expert panel
doi:10.1371/journal.pone.0030578.t001
Table 2. Model outputs indicating the number of harmed
patients per year.
Time (Year) 2008 2011 2014 2017 2020
VTE without HACS 19,500 20,560 21,279 21,679 22,040
VTE with HACS 19,500 8,050 7,661 7,770 7,898
Diagnosed VTE without HACS 16,575 17,151 17,913 18,316 18,631
Diagnosed VTE with HACS 16,575 7,428 5,834 5,803 5,892
Missed VTE without HACS 2,925 3,027 3,161 3,232 3,288
Missed VTE with HACS 2,925 2,359 1,939 1,934 1,964
Bleeding patients without
HACS
5,460 5,757 5,958 6,070 6,171
Bleeding patients with HACS 5,460 34,659 36,593 37,288 37,909
Bleeding without infection
without HACS
4,914 5,085 5,311 5,430 5,524
Bleeding without infection
with HACS
4,914 27,238 32,387 33,347 33,931
Infection without HACS 546 565 590 603 614
Infection with HACS 546 3,026 3,602 4,705 3,770
Ineligible patients without
HACS
0 0 0 0 0
Ineligible patients with HACS 0 35,751 38,543 39,335 39,993
Total harmed without HACS 0 15,698 17,175 17,689 18,018
Total harmed with HACS 0 51,387 64,038 66,454 67,680
doi:10.1371/journal.pone.0030578.t002
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Either a ‘‘carrot’’ or ‘‘stick’’ approach can be used to provide
monetary incentives to improve adherence to recommended care
guidelines. ‘‘Pay for performance’’ (P4P) rewards increased
adherence to quality metrics [46] while ‘‘hospital acquired
condition’’ penalizes undesirable outcomes. The amount of
increased guideline adherence varies across studies [47,48,49],
Figure 2. The fraction of patients harmed by HACS over time including sensitivity analysis adjustments.
doi:10.1371/journal.pone.0030578.g002
Figure 3. The fraction % of patients with osteoarthritis who might benefit from, but not receive TKA.
doi:10.1371/journal.pone.0030578.g003
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and these programs may either exacerbate [50,51,52] or reduce
racial disparity [46,49]. Underserved patients may experience
significant out-of-pocket costs so they may delay seeking of care,
both for the OA leading to TKA, but also for post-surgical
monitoring of emerging complications. An alternative to the
current approaches for rewarding guideline-based care might be to
reward those who provide high quality and equitable access to
underserved patients [48,53].
Although our study quantifies the relative impact of intended
and unintended consequences of the HACS policy, the model has
some limitations. First, model inputs were based on assumptions
drawn from publications. In cases where the data could not be
directly extracted from the literature and only approximations
were available, expert opinions from three surgeons in an
academic healthcare setting were obtained. Surgeons in other
settings may have opinions that differ, resulting in a greater or
lesser likelihood to treat patients with risk factors. However, the
dynamic nature of the model allows changing model parameters
whenever desired. Second, the relationship between age and
complication rates, or the effectiveness of VTE prophylaxis by risk
profile is not well documented in the literature. Consequences of
aggressive prophylaxis and the tendency to deny surgery to
subgroups of underserved patients were disregarded and would
need special attention. Third, we did not stratify complications by
severity. So potentially lethal and less harmful complications were
included in the same stock.
Our objective was to provide a range of potential outcomes
resulting from the Hospital Acquired Condition Strategy. A logical
extension could determine how HACS differently impacts various
at-risk populations. While it seems logical to propose process
variables such as VTE prophylaxis administration for measuring
quality of care, it is also clear that VTE is a problematic outcome
because it can occur even with proper prophylaxis [54,55,56,57].
Enforcing policies to prevent VTE can decrease access to care and
pose a theoretical risk of increasing overall complication rates.
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